The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial -

The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial
Information type: Other primary research
Source: European Heart Journal
Specialities: Cardiovascular system disorders | Nutritional and metabolic disorders
Summary
This analysis (n=17913) found that in patients with AF treated with oral anticoagulants, higher BMI was associated with a lower risk of all-cause mortality vs. normal BMI [overweight: HR 0.67 (95% CI 0.59–0.78); obese: HR 0.63 (95% CI 0.54–0.74), P < 0.0001].
UKMi comment
The analysis also found that in women, high waist circumference was associated with a 31% lower risk of all-cause mortality (p = 0.001), 27% lower risk of stroke, systemic embolism, MI or all-cause mortality (p= 0.001), and 28% lower risk of stroke or systemic embolism (p = 0.048) but not in men.
Related links: